Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25350503 | 1.00 | HTT (0.43) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL31561256 | 0.89 | MEN1 (0.45) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL30535450 | 0.85 | DHX9 (0.42) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL25352121 | 0.85 | MEN1 (0.41) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL25430854 | 0.85 | DHX9 (0.42) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL30535297 | 0.85 | MEN1 (0.41) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL25351911 | 0.83 | KAT6A (0.51) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL30535596 | 0.83 | KAT6A (0.51) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL25353685 | 0.73 | KAT6A (0.51) | HTTMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL30535678 | 0.73 | KAT6A (0.51) | HTTMEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025080900-A1 | INHIBITORS OF THE RNA HELICASE DHX9 FOR USE IN THE TREATMENT OF DNA DAMAGE REPAIR DEFICIENT, HOMOLOGOUS RECOMBINATION DEFICIENT, AND CANCERS HAVING A BRCA LOSS OF FUNCTION MUTATION | ACCENT THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | HTT 1061/4885MEN1 3318/4885ALDH1A1 1705/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | HTT 1177/4885MEN1 3191/4885ALDH1A1 1333/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | HTT 1061/4885MEN1 3318/4885ALDH1A1 1705/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | HTT 1177/4885MEN1 3191/4885ALDH1A1 1333/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | HTT 1031/4885MEN1 3047/4885ALDH1A1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.